GNF-5837
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406427

CAS#: 1033769-28-6

Description: GNF-5837 is a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF. The properties of GNF-5837 make it a good tool for the elucidation of TRK biology in cancer and other nononcology indications.


Chemical Structure

img
GNF-5837
CAS# 1033769-28-6

Theoretical Analysis

MedKoo Cat#: 406427
Name: GNF-5837
CAS#: 1033769-28-6
Chemical Formula: C28H21F4N5O2
Exact Mass: 535.16
Molecular Weight: 535.492
Elemental Analysis: C, 62.80; H, 3.95; F, 14.19; N, 13.08; O, 5.98

Price and Availability

Size Price Availability Quantity
10mg USD 110 Ready to ship
25mg USD 220 Ready to ship
50mg USD 385 Ready to ship
100mg USD 685 Ready to ship
200mg USD 1250 Ready to ship
500mg USD 2650 Ready to ship
1g USD 4350 Ready to ship
2g USD 7450 Ready to ship
Bulk inquiry

Synonym: GNF5837; GNF-5837; GNF 5837.

IUPAC/Chemical Name: (Z)-1-(3-((3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)amino)-4-methylphenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea

InChi Key: YYDUWLSETXNJJT-MTJSOVHGSA-N

InChi Code: InChI=1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14,33-34H,1H3,(H,36,38)(H2,35,37,39)/b21-12-

SMILES Code: O=C(NC1=CC(C(F)(F)F)=CC=C1F)NC2=CC=C(C)C(NC3=CC(NC/4=O)=C(C=C3)C4=C\C5=CC=CN5)=C2

Appearance: Orange to red solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:         

Biological target: GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC50 values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively).
In vitro activity: GNF‑5837, an inhibitor of TrkA and TrkB, suppressed the cell viability of renal carcinoma 786O and Caki‑2 cells in a concentration‑dependent manner. GNF‑5837 treatment led to decreased activities of TrkA and TrkB signaling, accompanied by reduced phosphorylation levels of AKT and extracellular signal‑regulated kinase (ERK) kinases, which was detected by western blot assay. GNF‑5837 induced G0/G1‑phase arrest and apoptosis. Consistently, GNF‑5837 affected the expression of p21, c‑Myc, and survivin proteins. Meanwhile, a wound healing assay showed that GNF‑5837 inhibited the migration ability of RCC cells by impairing Rac1 activity. GNF‑5837 also enhanced the cytotoxic effects of sunitinib via inhibition of ERK kinase. Reference: Oncol Rep. 2019 Nov;42(5):2039-2048. https://www.spandidos-publications.com/or/42/5/2039
In vivo activity: To determine the in vivo PK data, GNF-5837 (compound 22) was administered intravenously to male Balb/c mice and Sprague–Dawley rats, and the drug clearance was found to be low and the volume of distribution moderate (mice) to high (rat). When administered orally by gavage, it gave moderate biovailability in both mice and rats due to poor absorption deriving from a combination of poor permeability and low aqueous solubility (Table 3). In the mice, the drug concentration in the brain after oral delivery was below the limit of quantitation, suggesting that the compound does not effectively cross the blood–brain barrier. To demonstrate in vivo efficacy, compound 22 was administered at ascending doses once daily for 10 days in mice (Figure 2) with established tumor xenografts derived from RIE cells expressing both TRKA and NGF. In this study, 72 and 100% tumor regression was observed at 50 and 100 mg/kg, respectively. At 25 mg/kg, only partial tumor growth inhibition was achieved. Reference: ACS Med Chem Lett. 2012 Jan 1;3(2):140-5. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24900443/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 32.0 59.76

Preparing Stock Solutions

The following data is based on the product molecular weight 535.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol: 1. Chen Y, Wang H, Chen Y, Wang M, Ding G, Li T. Trk inhibitor GNF‑5837 suppresses the tumor growth, survival and migration of renal cell carcinoma. Oncol Rep. 2019 Nov;42(5):2039-2048. doi: 10.3892/or.2019.7296. Epub 2019 Aug 28. PMID: 31485624. 2. Aristizabal Prada ET, Heinzle V, Knösel T, Nölting S, Spöttl G, Maurer J, Spitzweg C, Angele M, Schmidt N, Beuschlein F, Stalla GK, Blaser R, Kuhn KA, Auernhammer CJ. Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. Endocr Relat Cancer. 2018 May;25(5):547-560. doi: 10.1530/ERC-17-0201. Epub 2018 Mar 21. PMID: 29563190.
In vivo protocol: 1. Albaugh P, Fan Y, Mi Y, Sun F, Adrian F, Li N, Jia Y, Sarkisova Y, Kreusch A, Hood T, Lu M, Liu G, Huang S, Liu Z, Loren J, Tuntland T, Karanewsky DS, Seidel HM, Molteni V. Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett. 2012 Jan 1;3(2):140-5. doi: 10.1021/ml200261d. PMID: 24900443; PMCID: PMC4025649.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 Pam Albaugh , Yi Fan , Yuan Mi , Fangxian Sun , Francisco Adrian , Nanxin Li , Yong Jia , Yelena Sarkisova , Andreas Kreusch , Tami Hood , Min Lu , Guoxun Liu , Shenlin Huang , Zuosheng Liu , Jon Loren , Tove Tuntland , Donald S. Karanewsky , H. Martin Seidel , and Valentina Molteni. Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med. Chem. Lett., 2012, 3 (2), pp 140–145.